| Business Summary | | Cytoclonal
Pharmaceutics
Inc.
is
a
biopharmaceutical
drug
development
company
specializing
in
therapeutic
products
for
human
diseases
with
an
emphasis
on
the
treatment
and
prevention
of
cancer
and
infectious
diseases.
To
date,
the
Company
has
been
involved
solely
in
research
and
development
activities
relating
to
several
proprietary
products
and
technologies
that
are
at
various
stages
of
development.
These
include
Paclitaxal,
the
active
ingredient
in
Taxol,
the
anti-cancer
agent
marketed
by
Bristol-Myers
Squibb.
The
Company
also
has
two
drug
design
platform
technologies:
Quantum
Core
Technologies
(QCT)
and
OASIS.
QCT
is
a
computer-assisted
drug
design
technology
platform,
primarily
targeted
to
inhibition
of
proteins
involved
in
disease.
OASIS
is
its
antisense
library
of
reagents
for
regulating
genes
involved
in
disease. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | CYPH,
a
development
stage
biopharmaceutical
company,
focuses
on
the
development
of
diagnostic
and
therapeutic
products
for
the
identification,
treatment,
and
prevention
of
cancer
and
infectious
diseases.
For
the
three
months
ended
3/31/01,
revenues
fell
3%
to
$333
thousand.
Net
loss
applicable
to
Common
fell
38%
to
$1.5
million.
Results
reflect
reduced
amounts
earned
under
the
agreement
with
Bristol-Myers
Squibb,
offset
by
lower
public
and
financial
relations
expenses. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
334;
after
tax
earnings
were
-2,949. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Gary Frashier, 64 Chairman | -- | Ronald Goode, Ph.D., 57 Pres,
CEO | -- | Arthur Bollon, Ph.D., 58 Vice
Chairman | $227K | Dorit Arad, Ph.D., 48 Exec.
VP of Drug Design | 132K | Joan Gillett, 51 VP,
Controller, and Principal Accounting Officer | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|